Works matching DE "PROMETHEUS Laboratories Inc."
Results: 23
THE PATENT ELIGIBILITY OF DIAGNOSTIC METHODS AFTER PROMETHEUS: A REDEFINED TEST FOR TRANSFORMATION.
- Published in:
- Health Matrix: Journal of Law-Medicine, 2012, v. 22, n. 2, p. 589
- By:
- Publication type:
- Article
A Judicial Axe for Sharp Drafting: The "Natural Phenomenon" Dilemma.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
§ 101 Patent Eligibility: Advocation of the Supreme Court Proffering a Bright-Line Rule.
- Published in:
- Texas Intellectual Property Law Journal, 2022, v. 31, n. 1, p. 37
- By:
- Publication type:
- Article
Testing times.
- Published in:
- Nature Genetics, 2012, v. 44, n. 5, p. 473, doi. 10.1038/ng.2264
- Publication type:
- Article
Recent Supreme Court Decisions Pose Roadblocks to Patent Eligibility.
- Published in:
- Advocate (05154987), 2022, v. 65, n. 9, p. 24
- By:
- Publication type:
- Article
Administering Mayo to Patents in Medicine and Biotechnology: Appropriate Dosage or Risk of Toxic Side Effects?
- Published in:
- Mercer Law Review, 2013, v. 64, n. 2, p. 573
- By:
- Publication type:
- Article
Mayo v Prometheus: The Eternal Conundrum of Patentability vs Patent-Eligibility.
- Published in:
- Journal of Intellectual Property Rights, 2014, v. 19, p. 371
- By:
- Publication type:
- Article
Diagnostic tests can be patented, rules US Court.
- Published in:
- Journal of Intellectual Property Rights, 2011, v. 16, n. 1, p. 53
- Publication type:
- Article
Genes involved in intestinal inflammatory diseases.
- Published in:
- Journal of Intellectual Property Rights, 2009, v. 14, n. 6, p. 570
- Publication type:
- Article
Patent Eligible Medical and Biotechnology Inventions After Bilski, Prometheus, and Myriad.
- Published in:
- Texas Intellectual Property Law Journal, 2011, v. 19, n. 3, p. 393
- By:
- Publication type:
- Article
Mayo "nays": The Supreme Court says no to patenting laws of nature.
- Published in:
- Journal of Commercial Biotechnology, 2012, v. 18, n. 3, p. 69, doi. 10.5912/jcb558
- By:
- Publication type:
- Article
PROMETHEUS LABORATORIES, MENTAL STEPS, AND PRINTED MATTER.
- Published in:
- Houston Law Review, 2012, v. 50, n. 2, p. 391
- By:
- Publication type:
- Article
Patent Eligibility and Cancer Therapy.
- Published in:
- Washington & Lee Law Review, 2022, v. 79, n. 1, p. 453
- By:
- Publication type:
- Article
The Impact of Uncertainty Regarding Patent Eligible Subject Matter for Investment in U.S. Medical Diagnostic Technologies.
- Published in:
- Washington & Lee Law Review, 2022, v. 79, n. 1, p. 397
- By:
- Publication type:
- Article
Stealing fire: a retrospective survey of biotech patent claims in the wake of Mayo v. Prometheus.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 8, p. 758, doi. 10.1038/nbt.2318
- By:
- Publication type:
- Article
Swiss food giant enters diagnostics.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 8, p. 672, doi. 10.1038/nbt0811-672b
- By:
- Publication type:
- Article
Surprise ruling eases diagnostic makers' fears.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 11, p. 963, doi. 10.1038/nbt1109-963b
- By:
- Publication type:
- Article
Deal watch: Phase III antibody targeting tumour pH acquired in Prometheus deal.
- Published in:
- 2011
- Publication type:
- journal article
Patent watch. Drug metabolite claims are patentable.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Prometheus and Bilski: pushing the bounds of patentable subject matter in medical diagnostic techniques with the machine-or-transformation test.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Prometheus v. Mayo: Is 35 U.S.C. § 101 a viable defense to patents claiming methods of optimizing therapeutic efficacy?
- Published in:
- Journal of Generic Medicines, 2010, v. 7, n. 2, p. 185, doi. 10.1057/jgm.2010.3
- By:
- Publication type:
- Article
Prometheus v. Mayo case in the spotlight.
- Published in:
- Nature Medicine, 2009, v. 15, n. 11, p. 1243, doi. 10.1038/nm1109-1243b
- By:
- Publication type:
- Article
The Entire Predictive Value of the Prometheus IBD sgi Diagnostic Product May be Due to the Three Least Expensive and Most Available Components.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2012, v. 107, n. 11, p. 1760, doi. 10.1038/ajg.2012.238
- By:
- Publication type:
- Article